• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HE Junjin, WANG Jiayi, HAO Jingchao, CHENG Haoran, XU Hanmei. Antitumor effect of peptide mPEG-SC20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(4): 476-480. DOI: 10.11665/j.issn.1000-5048.20150415
Citation: HE Junjin, WANG Jiayi, HAO Jingchao, CHENG Haoran, XU Hanmei. Antitumor effect of peptide mPEG-SC20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice[J]. Journal of China Pharmaceutical University, 2015, 46(4): 476-480. DOI: 10.11665/j.issn.1000-5048.20150415
shu

Antitumor effect of peptide mPEG-SC20k-HM-3 and oxaliplatin combination against human hepatocellular carcinoma SMMC-7721 in nude mice

More Information
    Graphical Abstract
    • Abstract
  • mPEG-SC20k-HM-3 is a novel anti-angiogenesis peptide with integrin affinity. To investigate the anti-tumor activities of mPEG-SC20k-HM-3 and oxaliplatin(OXA)combination, a transplanted tumor model of human hepatocellular carcinoma SMMC-7721 in nude mice was established. Jin′s formula to evaluate the combination effect was used. Data suggested that the anti-tumor activities of combined groups were better than those of single drug(P< 0. 05). Inhibition rate of group 8(OXA 7. 5 mg/kg and mPEG-SC20k-HM-3 73. 4 mg/kg)was 84. 6%, which showed remarkable superiority to group 3(OXA 7. 5 mg/kg)and group 4(mPEG-SC20k-HM-3 73. 4 mg/kg). The Q of group 8 was 1. 164(> 1. 15). This combination had synergistic effect. Combination of mPEG-SC20k-HM-3 and oxaliplatin is a method of inhibiting hepatocellular carcinoma.
    • FullText(HTML)
    • References (13)
  • [1]
    Enguita-Germán M,Fortes P.Targeting the insulin-like growth factor pathway in hepatocellular carcinoma[J].World J Hepatol,2014,6(10):716-737.
    [2]
    Morise Z,Kawabe N,Tomishige H,et al. Recent advances in the surgical treatment of hepatocellular carcinoma[J]. World J Gastroenterol,2014,20(39):14381-14392.
    [3]
    Folkman J.Tumorangiogenesis:therapeutic implication[J]. N Engl J Med,1971,285(21):1182-1186.
    [4]
    Dong J,Yao SW,Xu YG.Tumor angiogenesis inhibitors[J]. Prog Chem(化学进展),2010,22(10):1994-2002.
    [5]
    Wang JR,Li J,Lu BB,et al.Efficacy of bevacizumab combined with FOLFIRI in the treatment of refractory metatastic colorectal cancer[J].Mod Oncol(现代肿瘤医学),2013,21(3):578-581.
    [6]
    Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer[J]. N Engl J Med,2004,350(23):2335-2342.
    [7]
    Yang CX,Qin SK.Clinical study progression of oxaliplatin for primary hepaticcarcinoma[J].Chin Clin Oncol(临床肿瘤学杂志),2010,15(9):849-855.
    [8]
    Petrelli F,Coinu A,Borgonovo K,et al.Oxaliplatin-based chemotherapy:a new option in advanced hepatocellular carcinoma.A systematic review and pooled analysis[J].J Clin Oncol,2014, 26(8):488-496.
    [9]
    Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis correlation in invasive breast carcinoma[J].N Engl J Med,1991,324(1):1-8.
    [10]
    Bai LM,Huang XF,Xu HM.Investigation of microvessel density and related factors expression for xenografts tumor of HT29 cells in nude mice at different growth stage[J].Chin Pharmacol Bull(中国药理学报),2014,30(6):796-800.
    [11]
    Xv DZ.Evaluation of the combined effect of drugs[J].Prog Physiol Sci(生理科学进展),1992,23(3):248-253.
    [12]
    Jin ZJ,Zhang XW.Equi-probability sum curves and “Q50”[J].J Shanghai Second Hosp(上海第二医院学报),1981,1(1):15-18.
    [13]
    Abdel-Rahman O. Revisiting oxaliplatin-based regimens for advanced hepatocellular carcinoma[J].Curr Oncol Rep,2014,16(8):394.
    • Related Articles

  • Related Articles

    [1]YU Dan, CHAI Jian-guo, CAO Yan-guang, CHEN Yuan-cheng, LIU Xiao-quan. Effects of salvianolic acid B on the pharmacokinetics of danshensu in Danshen injection in rats[J]. Journal of China Pharmaceutical University, 2009, 40(3): 258-262.
    [2]Influence of Puerarin on Endogenous NOS Inhibitor of Human Umbilical Vein Endothelial Cells Cultured with Oxidized Low Density Lipoprotein[J]. Journal of China Pharmaceutical University, 2004, (4): 63-66.
    [3]Effects of Surfacant on the Dissolution of Puerarin Solid Dispersion[J]. Journal of China Pharmaceutical University, 2004, (4): 25-27.
    [4]Study on Microwave-assisted Extraction of Active Constituents in Radix Puerariae[J]. Journal of China Pharmaceutical University, 2002, (5): 26-29.
    [5]Inhibition of Puerarin on the H_2O_2-induced Apoptosis of Smooth Muscle Cells[J]. Journal of China Pharmaceutical University, 2002, (3): 75-78.
    [6]Determination of SalvianicAcid and Protocatechuic Aldehyde in Injectio Salvia Miltiorrhiza Composita by HPCE[J]. Journal of China Pharmaceutical University, 2001, (2): 50-52.
    [7]Determination of Purearinin Dog Plasma after Oral Administration of Puerarin lobata Recipe by HPLC[J]. Journal of China Pharmaceutical University, 2001, (2): 47-49.
    [8]Preparation and Bio activity of Puerarin Derivatives[J]. Journal of China Pharmaceutical University, 1999, (2): 3-7.
    [9]Studies on Lowing IOP Effect of Puerarin Eyedrops[J]. Journal of China Pharmaceutical University, 1998, (5): 67-69.
    [10]Studies on Pharmacokinetics of Puerarin Eyedrops[J]. Journal of China Pharmaceutical University, 1998, (3): 71-74.

Catalog

    Get Citation
    PDF
    XML
    Article views (1394) PDF downloads (1948) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：278778

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return